Blood Cancer Program

Jade Clarson
- Chronic Myeloid Leukaemia Group - Research Officer
Person: Academic
20172023
Phuong Dang
- Chronic Myeloid Leukaemia Group - Research Officer
Person: Academic
20062023
Laura Eadie
- laura.eadiesahmricom
- Acute Lymphoblastic Leukaemia Group - Postdoctoral Researcher
Person: Academic
20082024

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
Eadie, L. N., Lagonik, E., Page, E. C., Schutz, C. E., Heatley, S. L., McClure, B. J., Forgione, M. O., Yeung, D. T., Hughes, T. P. & White, D. L., 2024, (Accepted/In press) In: Blood.
Research output: Contribution to journal › Article › peer-review
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Cortes, J. E., Sasaki, K., Kim, D. W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., Deininger, M., Goh, Y. T., Janssen, J. J. W. M., Talpaz, M., de Soria, V. G. G., le Coutre, P., DeAngelo, D. J., Damon, A., Cacciatore, S. & Polydoros, F. & 2 others, Agrawal, N. & Rea, D., 2024, (Accepted/In press) In: Leukemia.
Research output: Contribution to journal › Article › peer-review

Open Access

4 Citations (Scopus)
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., Ratnasingam, S., Raj, S., Lukito, P., Yeung, D., Hughes, T. & Shanmuganathan, N., 2024, (Accepted/In press) In: Internal Medicine Journal.
Research output: Contribution to journal › Article › peer-review

Open Access

Collaborations and top research areas from the last five years